The global market for Intravenous (IV) Iron Drugs was estimated at US$3.2 Billion in 2024 and is projected to reach US$4.8 Billion by 2030, growing at a CAGR of 7.1% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Intravenous (IV) Iron Drugs market.
The growth in the intravenous (IV) iron drugs market is driven by several factors, including technological advancements in drug formulations, expanding indications for IV iron therapy, and increasing awareness among healthcare providers and patients about the benefits of IV iron. The development of newer, safer formulations that allow for higher doses and quicker administration has significantly enhanced the appeal of IV iron therapies. Additionally, the rising prevalence of chronic diseases such as chronic kidney disease, cancer, and heart failure, which are often associated with iron deficiency, has created a higher demand for effective iron supplementation methods. The expanding applications of IV iron in managing these conditions, coupled with improved diagnostic capabilities, have also contributed to market growth. Furthermore, the growing emphasis on outpatient care and the reduction of hospital stay durations are influencing the adoption of IV iron treatments, as they align with the broader healthcare trend towards more efficient and patient-friendly therapeutic options.
The global intravenous iron drugs market, therefore, is forecast to witness a steady growth, driven by the increase in aging population, growing life expectancy rate, growing incidence of CKD, and rise in number of ESRD patients. Other factors driving growth include increasing healthcare expenditure, rising urbanization, and favorable guidelines laid down by healthcare organizations. Furthermore, the market is also witnessing rapid transition in terms of demand from traditional dextran to non-dextran intravenous iron drugs. Non-dextran intravenous iron drug offer higher advantageous over dextran intravenous iron drugs in terms of delivering higher doses of infusing iron in a shorter time period. Additionally, the non-dextran based drugs are capable of addressing various challenges, such as safety, intolerance, dosing, and compliance associated with traditional iron therapies.
Global Intravenous (IV) Iron Drugs Market - Key Trends & Drivers Summarized
Intravenous (IV) iron drugs are essential treatments used primarily for addressing iron deficiency anemia, a condition where the body lacks sufficient iron to produce healthy red blood cells. These drugs are administered directly into the bloodstream, allowing for quick and efficient absorption, especially in patients who cannot tolerate or adequately absorb oral iron supplements. IV iron therapy is crucial for patients with chronic kidney disease, inflammatory bowel disease, heart failure, and those undergoing chemotherapy, as these conditions often result in significant iron loss or hinder the absorption of iron. Various formulations of IV iron, such as iron sucrose, ferric carboxymaltose, and iron dextran, have been developed to optimize their efficacy and safety, minimizing potential side effects like allergic reactions or anaphylaxis. The advancement in these formulations has made it possible to deliver higher doses in a single session, improving patient compliance and outcomes.The growth in the intravenous (IV) iron drugs market is driven by several factors, including technological advancements in drug formulations, expanding indications for IV iron therapy, and increasing awareness among healthcare providers and patients about the benefits of IV iron. The development of newer, safer formulations that allow for higher doses and quicker administration has significantly enhanced the appeal of IV iron therapies. Additionally, the rising prevalence of chronic diseases such as chronic kidney disease, cancer, and heart failure, which are often associated with iron deficiency, has created a higher demand for effective iron supplementation methods. The expanding applications of IV iron in managing these conditions, coupled with improved diagnostic capabilities, have also contributed to market growth. Furthermore, the growing emphasis on outpatient care and the reduction of hospital stay durations are influencing the adoption of IV iron treatments, as they align with the broader healthcare trend towards more efficient and patient-friendly therapeutic options.
The global intravenous iron drugs market, therefore, is forecast to witness a steady growth, driven by the increase in aging population, growing life expectancy rate, growing incidence of CKD, and rise in number of ESRD patients. Other factors driving growth include increasing healthcare expenditure, rising urbanization, and favorable guidelines laid down by healthcare organizations. Furthermore, the market is also witnessing rapid transition in terms of demand from traditional dextran to non-dextran intravenous iron drugs. Non-dextran intravenous iron drug offer higher advantageous over dextran intravenous iron drugs in terms of delivering higher doses of infusing iron in a shorter time period. Additionally, the non-dextran based drugs are capable of addressing various challenges, such as safety, intolerance, dosing, and compliance associated with traditional iron therapies.
Scope of Study:
The report analyzes the Intravenous (IV) Iron Drugs market in terms of units by the following Segments, and Geographic Regions/Countries:- Segments: Product Type (Ferric Carboxymaltose, Iron Dextran, Iron Sucrose, Other Product Types); Application (Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease, Other Applications)
- Geographic Regions/Countries: World; USA; Canada; Japan; China; Europe; France; Germany; Italy; UK; Spain; Russia; Rest of Europe; Asia-Pacific; Australia; India; South Korea; Rest of Asia-Pacific; Latin America; Argentina; Brazil; Mexico; Rest of Latin America; Middle East; Iran; Israel; Saudi Arabia; UAE; Rest of Middle East; Africa.
Key Insights:
- Market Growth: Understand the significant growth trajectory of the Ferric Carboxymaltose segment, which is expected to reach US$2.3 Billion by 2030 with a CAGR of a 7.5%. The Iron Dextran segment is also set to grow at 6.4% CAGR over the analysis period.
- Regional Analysis: Gain insights into the U.S. market, estimated at $1.1 Billion in 2024, and China, forecasted to grow at an impressive 10.6% CAGR to reach $658.4 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Why You Should Buy This Report:
- Detailed Market Analysis: Access a thorough analysis of the Global Intravenous (IV) Iron Drugs Market, covering all major geographic regions and market segments.
- Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
- Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Intravenous (IV) Iron Drugs Market.
- Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.
Key Questions Answered:
- How is the Global Intravenous (IV) Iron Drugs Market expected to evolve by 2030?
- What are the main drivers and restraints affecting the market?
- Which market segments will grow the most over the forecast period?
- How will market shares for different regions and segments change by 2030?
- Who are the leading players in the market, and what are their prospects?
Report Features:
- Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
- In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
- Company Profiles: Coverage of players such as AbbVie Inc (AbbVie), Akebia Therapeutics, Inc., American Regent, Inc., Covis Pharma GmbH., Daiichi Sankyo Company, Ltd. and more.
- Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Some of the 33 companies featured in this Intravenous (IV) Iron Drugs market report include:
- AbbVie Inc (AbbVie)
- Akebia Therapeutics, Inc.
- American Regent, Inc.
- Covis Pharma GmbH.
- Daiichi Sankyo Company, Ltd.
- Galenica Group
- Iron4u Aps
- NIPPON SHINYAKU CO., LTD.
- Pharmacosmos A/S
- Rockwell Medical, Inc.
- Sanofi S.A.
- Shield Therapeutics Plc
- Vifor Pharma Management Ltd.
This edition integrates the latest global trade and economic shifts as of June 2025 into comprehensive market analysis. Key updates include:
- Tariff and Trade Impact: Insights into global tariff negotiations across 180+ countries, with analysis of supply chain turbulence, sourcing disruptions, and geographic realignment. Special focus on 2025 as a pivotal year for trade tensions, including updated perspectives on the Trump-era tariffs.
- Adjusted Forecasts and Analytics: Revised global and regional market forecasts through 2030, incorporating tariff effects, economic uncertainty, and structural changes in globalization. Includes segmentation by product, technology, type, material, distribution channel, application, and end-use, with historical analysis since 2015.
- Strategic Market Dynamics: Evaluation of revised market prospects, regional outlooks, and key economic indicators such as population and urbanization trends.
- Innovation & Technology Trends: Latest developments in product and process innovation, emerging technologies, and key industry drivers shaping the competitive landscape.
- Competitive Intelligence: Updated global market share estimates for 2025, competitive positioning of major players (Strong/Active/Niche/Trivial), and refined focus on leading global brands and core players.
- Expert Insight & Commentary: Strategic analysis from economists, trade experts, and domain specialists to contextualize market shifts and identify emerging opportunities.
- Complimentary Update: Buyers receive a free July 2025 update with finalized tariff impacts, new trade agreement effects, revised projections, and expanded country-level coverage.
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERS
1. MARKET OVERVIEW
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
III. MARKET ANALYSIS
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie Inc (AbbVie)
- Akebia Therapeutics, Inc.
- American Regent, Inc.
- Covis Pharma GmbH.
- Daiichi Sankyo Company, Ltd.
- Galenica Group
- Iron4u Aps
- NIPPON SHINYAKU CO., LTD.
- Pharmacosmos A/S
- Rockwell Medical, Inc.
- Sanofi S.A.
- Shield Therapeutics Plc
- Vifor Pharma Management Ltd.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 354 |
| Published | June 2025 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value ( USD | $ 3.2 Billion |
| Forecasted Market Value ( USD | $ 4.8 Billion |
| Compound Annual Growth Rate | 7.1% |
| Regions Covered | Global |
